INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of

INDEX TO FINANCIAL STATEMENTS

REPORT OF INDEPENDENT REGISTERED PUBLIC

To the Stockholders and the Board of Directors

Amplitude Healthcare Acquisition Corporation

Opinion on the Financial Statements

We have audited the accompanying balance

sheet of Amplitude Healthcare Acquisition Corporation (the "Company") as of November 22, 2019 and the related notes

(collectively referred to as the "financial statement"). In our opinion, the financial statement presents fairly, in

all material respects, the financial position of the Company as of November 22, 2019, in conformity with accounting principles

generally accepted in the United States of America.

This financial statement is the responsibility

of the Company's management. Our responsibility is to express an opinion on the Company's financial statement based on our audit.

We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB")

and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable

rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with

the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether

the financial statement is free of material misstatement, whether due to error or fraud. The Company is not required to have, nor

were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to

obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness

of the entity's internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures

to assess the risks of material misstatement of the financial statement, whether due to error or fraud, and performing procedures

that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures

in the financial statement. Our audit also included evaluating the accounting principles used and significant estimates made by

management, as well as evaluating the overall presentation of the financial statement. We believe that our audit provides a reasonable

basis for our opinion.

/s/ WithumSmith+Brown, PC

We have served as the Company's auditor

AMPLITUDE HEALTHCARE ACQUISITION CORPORATION

The accompanying notes are an integral part

of this financial statement.

AMPLITUDE HEALTHCARE ACQUISITION CORPORATION

NOTES TO FINANCIAL STATEMENT

Note 1 - Description

of Organization and Business Operations

Amplitude Healthcare

Acquisition Corporation (the "Company") was incorporated in Delaware on August 13, 2019. The Company was formed for

the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination

with one or more businesses (the "Business Combination").

Although the Company

is not limited to a particular industry or sector for purposes of consummating a Business Combination, the Company intends to focus

its search on companies in the healthcare industry. The Company is an early stage and emerging growth company and, as such, the

Company is subject to all of the risks associated with early stage and emerging growth companies.

As of November 22, 2019,

the Company had not commenced any operations. All activity for the period from August 13, 2019 (inception) through November 22,

2019 relates to the Company's formation and the initial public offering ("Initial Public Offering"), which is

described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination,

at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the

Initial Public Offering.

statement for the Company's Initial Public Offering was declared effective on November 19, 2019. On November 22, 2019, the

Company consummated the Initial Public Offering of 10,000,000 units (the "Units" and, with respect to the shares of

Class A common stock included in the Units sold, the "Public Shares"), generating gross proceeds of $100,000,000, which

is described in Note 3.

the closing of the Initial Public Offering, the Company consummated the sale of 4,000,000 warrants (the "Private Placement

Warrants") at a price of $1.00 per Private Placement Warrant in a private placement to Amplitude Healthcare Holdings LLC,

a Delaware limited liability company (the "Sponsor"), generating gross proceeds of $4,000,000, which is described in

amounted to $5,944,772, consisting of $2,000,000 of underwriting fees, $3,500,000 of deferred underwriting fees and $444,772 of

other offering costs. In addition, $1,555,205 of cash was held outside of the Trust Account (as defined below) and is available

for working capital purposes.

Following the closing

of the Initial Public Offering on November 22, 2019, an amount of $100,000,000 ($10.00 per Unit) from the net proceeds of the sale

of the Units in the Initial Public Offering and the sale of the Private Placement Warrant was placed in a trust account ("Trust

Account") which will be invested only in U.S. government securities, within the meaning set forth in Section 2(a)(16) of

the Investment Company Act, with a maturity of 180 days or less or in any open-ended investment company that holds itself out as

a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined

by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust

Account, as described below.

management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and

the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward

consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully.

The Company must complete a Business Combination with one or more target businesses that together have an aggregate fair market

value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable

on interest earned on the Trust Account) at the time of the agreement to enter into a Business Combination. The Company will only

complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities

of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an

investment company under the Investment Company Act 1940, as amended (the "Investment Company Act").

The Company will provide

its holders of the outstanding Public Shares (the "Public Stockholders") with the opportunity to redeem all or a portion

of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called

to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder

approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public

Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially

anticipated to be $10.00 per Public Share, plus any pro rata interest earned on the funds held in the Trust Account and not previously

released to the Company to pay its tax obligations). The per-share amount to be distributed to Public Stockholders who redeem their

Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed

in Note 6). There will be no redemption rights upon the completion of a Business Combination with respect to the Company's

AMPLITUDE HEALTHCARE ACQUISITION CORPORATION

NOTES TO FINANCIAL STATEMENT

The Company will proceed

with a Business Combination if the Company has net tangible assets of at least $5,000,001 immediately prior to or upon such consummation

of a Business Combination and, if the Company seeks stockholder approval, a majority of the shares voted are voted in favor of

the Business Combination. If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote

for business or other legal reasons, the Company will, pursuant to its Certificate of Incorporation (the "Certificate of

Incorporation"), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission

("SEC") and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder

approval of the transactions is required by law, or the Company decides to obtain stockholder approval for business or legal reasons,

the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to